ALXA: ALEXZA PHARMACEUTICALS INC Profile

Ticker

Advertisement

Choose a Broker

Dynamic view of the market

U.S. Markets open in 5 hrs, 34 mins

Symbol	Value	Change	Percentage Change
DJIA	11,384.21	152.25	1.36%
NASDAQ	2,294.44	51.12	2.28%
S&P 500	1,273.70	21.39	1.71%

ALEXZA PHARMACEUTICALS INC

ALXA

Stock price

4.43 0.42 10.47%

as of 04:00 PM EDT on 07/08/2008 in USD (NASDAQ Delay: 15 mins.)
Extended Hours

4.2305 -0.1995 -4.50%

as of 04:16 PM EDT on 07/08/08

Analyst Consensus

Buy
Analyst Consensus

Strong Buy

Buy

Hold

Sell

Strong Sell
- Add to Portfolio
- Add to Alerts

Insightful information about industries, companies, and the people who lead them.

Learn More.

2006 Sales	2006 Sales Growth	2006 Net Income	2006 Employees
$1,000,000	-53.8%	$-41,800,000	141

Key Executives: ALXA

Name	Title	Officer Since
Thomas B. King	CEO	6/1/03
August J. Moretti	CFO	-
Dr. Deepika R. Pakianathan, Ph.D.	Director	11/1/04
Dr. J. Leighton Read, M.D.	Director	11/1/04
Dr. Gordon Ringold, Ph.D.	Director	6/1/01
Alejandro A. Zaffaroni, M.D.	—	-
Isaac Stein, J.D.	Director	6/1/01
Alan D. Frazier	Director	9/1/02

View All Key Executives

Thomas B. King has served as our President, Chief Executive Officer and a member of our Board since June 2003. From September 2002 to April 2003, Mr. King served as President, Chief Executive Officer and a member of the board of directors of Cognetix, Inc., a biopharmaceutical development company. From January 1994 to February 2001, Mr. King held various senior executive positions, including President and Chief Executive Officer from January 1997... View Full Profile

Thomas B. King

August J. Moretti has served as our Senior Vice President and Chief Financial Officer since February 2005 and as our Secretary since December 2005. From August 2004 to February 2005, Mr. Moretti was our part time Chief Financial Officer. From January 2001 to January 2005, Mr. Moretti served as Chief Financial Officer and General Counsel at Alavita, Inc. (formerly known as SurroMed, Inc.), a biotechnology company. From January 1982 to December... View Full Profile

August J. Moretti

Deepika R. Pakianathan, Ph.D. has served as a member of our Board since November 2004. Since 2001, Dr. Pakianathan has served as a general partner at Delphi Ventures, a venture capital firm focusing on healthcare investments. From 1998 to 2001, Dr. Pakianathan was a senior biotechnology banker at JPMorgan. Prior to joining JP Morgan, Dr. Pakianathan was a research analyst at Genesis Merchant Group, a private investment partnership, from 1997 to... View Full Profile

Dr. Deepika R. Pakianathan, Ph.D.

J. Leighton Read, M.D. has served as a member of our Board since November 2004. Since 2001, Dr. Read has served as a general partner of Alloy Ventures, a venture capital firm. Dr. Read founded Aviron, a biopharmaceutical company, and served as its Chief Executive Officer until 1999. In 1989, Dr. Read co-founded Affymax NV, a biopharmaceutical company. Dr. Read is a member of the board of directors of various private companies. Dr. Read has... View Full Profile

Dr. J. Leighton Read, M.D.

Gordon Ringold, Ph.D. has served as a member of our Board since June 2001. Since March 2000, Dr. Ringold has served as Chairman and Chief Executive Officer of Alavita, Inc. From March 1995 to February 2000, Dr. Ringold served as Chief Executive Officer and Scientific Director of Affymax Research Institute where he managed the development of novel technologies to accelerate the pace of drug discovery. Dr. Ringold is also a member of the board of... View Full Profile

Dr. Gordon Ringold, Ph.D.

Gordon Ringold, Ph.D. has served as a member of our Board since June 2001. Since March 2000, Dr. Ringold has served as Chairman and Chief Executive Officer of Alavita, Inc. From March 1995 to February 2000, Dr. Ringold served as Chief Executive Officer and Scientific Director of Affymax Research Institute where he managed the development of novel technologies to accelerate the pace of drug discovery. Dr. Ringold is also a member of the board of... View Full Profile

Alejandro A. Zaffaroni, M.D.

Isaac Stein has served as a member of our Board since June 2001. Since November 1982, Mr. Stein has been President of Waverley Associates, Inc., a private investment firm. He is also the emeritus Chairman of the Board of Trustees of Stanford University and is the Chairman of the board of directors of Maxygen, Inc. Mr. Stein is also a director of American Balanced Fund, Inc. and The Income Fund of America, Inc., each a publicly traded investment... View Full Profile

Isaac Stein, J.D.

Alan D. Frazier has served as a member of our Board since September 2002. In 1991, Mr. Frazier founded Frazier Healthcare Ventures, a venture capital firm, and has served as the managing principal since its inception. From 1983 to 1991, Mr. Frazier served as Executive Vice President, Chief Financial Officer and Treasurer of Immunex Corporation, a publicly traded biopharmaceutical company. From 1980 to 1983, Mr. Frazier was a principal in the... View Full Profile

Alan D. Frazier

Samuel D. Colella has served as a member of our Board since September 2002. In 1999, Mr. Colella co-founded Versant Ventures, a venture capital firm, and has served as a managing member since its formation. Prior to founding Versant Ventures, Mr. Colella has served as general partner of Institutional Venture Partners, a venture capital firm, since 1984. Mr. Colella is a member of the board of directors of Genomic Health, Inc., a publicly traded... View Full Profile

Samuel D. Colella

Anthony G. Tebbutt has served as our Senior Vice President, Corporate Strategy and Business Development since March 2007. From September 1996 to October 2006, Mr. Tebbutt served as Senior Vice President and President at UCB, SA (Belgium), a pharmaceutical company, and from 1983 to 1995 Mr. Tebbut served in various Vice President positions in New Product Planning and Marketing for Syntex Laboratories, a publicly traded pharmaceutical company.... View Full Profile

Anthony G. Tebbutt

Hal V. Barron, M.D., FACC has served as a member of our Board since December 2007. Since December 2003, Dr. Barron has served as Senior Vice President of Development and as Chief Medical Officer since March 2004 at Genentech, Inc., a publicly traded biotechnology company. Dr. Barron joined Genentech in 1996 as a clinical scientist and in 2002 he was promoted to Vice President of Medical Affairs. Dr. Barron"s academic positions include Associate... View Full Profile

Dr. Hal V. Barron, M.D.

Robert S. Fishman, M.D., F.C.C.P. has served as our Vice President, Medical Affairs since September 2007. Dr. Fishman was most recently Senior Vice President, Clinical Development for Anthera Pharmaceuticals, Inc., a privately held pharmaceutical company, from 2005 to 2007. Previously, he was Vice President, Scientific Affairs for Aerogen, Inc., a publicly traded specialty pharmaceutical company, where he served in various capacities from 1998 to... View Full Profile

Dr. Robert S. Fishman, M.D.

Michael J. Simms has served as our Senior Vice President, Operations and Manufacturing since February 2008. From May 2007 to February 2008 Mr. Simms served as Senior Vice President, Manufacturing Operations and from June 2004 to May 2007 served as Vice President, Manufacturing of Nektar Therapeutics, a publicly traded biopharmaceutical company. From August 2002 to June 2004, Mr. Simms worked as an independent consultant to develop manufacturing... View Full Profile

Michael J. Simms

Michael J. Simms has served as our Senior Vice President, Operations and Manufacturing since February 2008. From May 2007 to February 2008 Mr. Simms served as Senior Vice President, Manufacturing Operations and from June 2004 to May 2007 served as Vice President, Manufacturing of Nektar Therapeutics, a publicly traded biopharmaceutical company. From August 2002 to June 2004, Mr. Simms worked as an independent consultant to develop manufacturing... View Full Profile

Jeffrey S. Williams

William C. Houghton, M.D. has served as our Vice President, Clinical and Regulatory Affairs since November 2005. From June 2005 to November 2005, Dr. Houghton served as Vice President of Clinical Development at Jazz Pharmaceuticals, Inc., a pharmaceutical company. From August 1998 to June 2005, Dr. Houghton held various management positions, including Chief Operating Officer from August 1998 to May 2002, at Orphan Medical, Inc., a publicly traded... View Full Profile

Dr.William C. Houghton, M.D.

Emily Lee Kelley has served as our Vice President, Human Resources since October 2002. From October 2001 to October 2002, Ms. Kelley provided human resources consulting services to us and Versicor, Inc., a majority owned subsidiary of Sepracor Inc., a publicly traded pharmaceutical company. From 1995 to 2001, Ms. Kelley served as Vice President of Human Resources, Finance and Operations at Affymax Research Institute, a pharmaceutical company, and... View Full Profile

Emily Lee Kelley

William L. Leschensky, M.D., J.D. has served as our Vice President, Intellectual Property since November 2005. From December 2004 to October 2005, he was our Senior Director, Intellectual Property. From May 2000 to December 2004, Dr. Leschensky was in-house intellectual property counsel at Alavita, Inc., and from September 1992 to May 2000, Dr. Leschensky was an intellectual property attorney at the law firms of Fish & Neave LLP and Morrison &... View Full Profile

Dr. William L. Leschensky, M.D., J.D.

Joseph L. Baker has served as our Vice President, Commercial Manufacturing and Global Supply Chain since November 2006. From 1999 to 2006, Mr. Baker was General Manager for Watson Laboratories, Inc., a subsidiary of Watson Pharmaceuticals, Inc., a publicly traded specialty pharmaceutical company, where he was responsible for all activities for the Salt Lake City manufacturing facility. He was previously Director, Oral Product R&D and Director,... View Full Profile

Joseph L. Baker

Michael J. Taylor, Ph.D., DABT has served as our Vice President, Preclinical Development since August 2006. From January 2005 to August 2006, Dr. Taylor was Sr. Director, Preclinical and Clinical Development Sciences for Protein Design Labs, Inc., a publicly traded biopharmaceutical company. From April 2000 to January 2005, Dr. Taylor was Vice President, Non-Clinical Research and Development and Executive Director, Drug Safety and Evaluation for... View Full Profile

Dr. Michael J. Taylor, Ph.D.

James V. Cassella, Ph.D. has served as our Senior Vice President, Research and Development since June 2004. From April 1989 to April 2004, Dr. Cassella held various management positions at Neurogen Corporation, a publicly traded biotechnology company, including Senior Vice President of Clinical Research and Development from January 2003 to June 2004. Prior to Neurogen, Dr. Cassella was Assistant Professor of Neuroscience at Oberlin College. Dr.... View Full Profile

James V. Cassella, Ph.D.

Top Competitors: ALXA

View Detailed Competitors Chart

Insider Trends: ALXA
Sentiment for ALXA is NEGATIVE
- 0M
- 2M
- 4M
- 6M
- Market Value of Insider Sales
- Market Value of Insider Purchases
Total dollar value of all insider purchases and sales over 12 months
View All Insider Sentiment

Insider Transactions: ALXA

Date	Name	Shares	Transaction Type	Market Value
05/15/08	RINGOLD GORDON	7,000	Purchase	$41,720.00
05/12/08	KING THOMAS BRAXTON	12,500	Planned Sale	$76,476.30
05/12/08	KING THOMAS BRAXTON	12,500	Sale	$76,476.00

View All Insider Activity

Ownership Breakdown : ALXA

Large Block Holder Type	Number
Institutions	66.00
Mutual Fund	86.00
Other Major	11.00

Full Details

Indices : ALXA

Symbol	Name	Last Trade	Change
$RUT.X	Russell 2000 Index	—	——%

View all Indices that include ALXA

Short Interest Volume: ALXA

Data as of 6/10/08

Current Short Interest Shares	1.10 B
Current Short Interest Ratio	19.20
Float	30.42 M

Short Interest as % of Float	9.70
Average Daily Volume	166,000.00
Outstanding Shares	32.58 M

Full Details

SEC Filings: ALXA

Accepted Date	Description
06/09/2008	SEC Filing: Current Event
05/30/2008	SEC Filing: Employee benefit Plans
05/30/2008	SEC Filing: Current Event

View all SEC Filings

Get Profile Details for:

- Help & Feedback

Market Movers

Related Resources

My Portfolios

AOL Real-Time Streaming Quotes

ALEXZA PHARMACEUTICALS INC

ALXA

Stock price

4.43 0.42 10.47%

as of 04:00 PM EDT on 07/08/2008 in USD (NASDAQ Delay: 15 mins.)
Analyst Consensus
- Strong Buy
- Buy
- Hold
- Sell
- Strong Sell
- Add to Portfolio
- Add to Alerts

Quote Search Search the Web Search

More in Money & Finance
- Money
- Earnings
- Tech News
- Stock Screener
- Banking
- Checking Account
- Savings Account
- Credit Cards
- Credit Reports
- Identity Theft
- Debt Management
- Loans
- Auto Loan
- Personal Loans
- Mortgages
- Refinancing
- Taxes
- Online Tax Filing
- Tax Advice
- Tax Basics
- Tax Forms
- Audit
- Tax Credit
- Tax Deduction
- AMT
- Small Business
- BloggingStocks
- BloggingBuyouts
- Luxist
- TUAW
- DJIA
- Dow Jones Industrial Average
More Stock Research
Notices and Terms: Confirm all data with your broker before trading.

Quote data provided by Interactive Data. Historical prices provided by Prophet. Company Profile provided by Hoovers. Executive data and Industry/Sector information provided by Morningstar Inc. Earnings, Ownership, Financial Statement, Insider Trading, Conference Call schedules and SEC Filing information provided by Thomson Financial.

Live Updates:

Ticker

Dynamic view of the market

ALEXZA PHARMACEUTICALS INC

ALXA

Stock price

Extended Hours

Analyst Consensus

ALEXZA PHARMACEUTICALS INC Profile

Key Executives: ALXA

Top Competitors: ALXA

Insider Trends: ALXA

Insider Transactions: ALXA

Ownership Breakdown : ALXA

Indices : ALXA

Short Interest Volume: ALXA

SEC Filings: ALXA

Quote Details

Classic Chart

Advanced Chart BETA

Real-Time Headlines

Message Boards

Profile

Earnings Analysis

Event Calendar

Financials

Market Movers

Related Resources

ALEXZA PHARMACEUTICALS INC

ALXA

Stock price

Analyst Consensus

More in Money & Finance

More Stock Research